美国明尼阿波利斯消息:叠氮胸腺嘧啶核苷(AZT),也称S化合物和BW A509U,是人亲T淋巴细胞病毒-Ⅲ(HTLV-Ⅲ)逆转录酶的竞争抑制剂,可通过干扰病毒逆转录酶链的延伸而起作用。此药的Ⅰ期试验已在国立癌症研究所(NCI)和Duke大学开始,目前已有9名患者参加试验,预期1986年初能开始第Ⅱ期实验研究。尚未发现此药有何毒性,还不能确定使用的剂量。人细胞体外研究表明,AZT能降低HTLV-Ⅲ的复制能力。似乎也能在病毒杀伤细胞时保护T细胞。对抗在遗传上不同的病毒株。 Minneapolis, MN, USA AZT, also known as S and BW A509U, is a competitive inhibitor of human pro-T Lymphocytic Virus-III (HTLV-III) reverse transcriptase by Interfere with the extension of the virus reverse transcriptase chain and work. Phase I trials of this drug have been started at the National Cancer Institute (NCI) and Duke University. Nine patients have been included in the trial and Phase II trials are expected to begin in early 1986. The drug has not yet found any toxicity, but also can not determine the dose used. In vitro studies of human cells show that AZT can reduce the replication of HTLV-III. Seems to also protect T cells when the virus kills the cells. Fight against genetically different virus strains.